Lv63
3060 积分 2021-12-27 加入
A Phase I/IIa Trial of Yttrium-90 Radioembolization in Combination with Durvalumab for Locally Advanced Unresectable Hepatocellular Carcinoma
3小时前
已完结
Management, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitors
30天前
已完结
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events
3个月前
已完结
Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management
3个月前
已完结
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
5个月前
已完结
[Expert consensus on the diagnosis and treatment of esophageal and gastric variceal rupture bleeding in cirrhotic portal hypertension (2024 edition)]
5个月前
已完结
What Is the Optimal Locoregional Approach for Recurrent Hepatocellular Carcinoma?
6个月前
已关闭
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
7个月前
已完结
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events
7个月前
已完结
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
7个月前
已完结
皖公网安备34019202002308
